Despite being a mainstay of Parkinson's disease treatment, levodopa, a dopamine-replenishing medication, can cause nasty side-effects with long-term use. A recent human trial found that a new drug ...

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with advanced Parkinson’s disease. This novel treatment is the first of its kind, ...

The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...

Medically reviewed by Nicholas R. Metrus, MD Key Takeaways Facial masking is a common symptom seen in people with Parkinson's ...

In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a ...

University of Arizona researchers have revealed new insights into the neurobiological cause of the involuntary, uncontrollable movement disorders that develop in patients with Parkinson’s disease (PD) ...

CREXONT ® is a novel, oral formulation of carbidopa/levodopa (CD/LD) capsule that combines both immediate-release granules and extended-release beads for the treatment of Parkinson’s disease. CREXONT ...

The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations. Propranolol, however, does work during stress, providing insight into ...

Explore Duopa, an advanced Parkinson's disease treatment that uses carbidopa-levodopa gel infusion for steady dopamine levels, reducing motor fluctuations effectively.

The FDA extended its decision date for investigational tolebrutinib in non-relapsing, secondary progressive multiple sclerosis (MS) to December 28, Sanofi said. The agency also opted to not approve ...